Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.89 USD
+0.04 (1.23%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.88 -0.01 (-0.35%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Earnings News For ALLO
-
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
-
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
-
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
-
Allogene Therapeutics: Q4 Earnings Snapshot
-
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
-
Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss
-
Allogene Therapeutics: Q3 Earnings Snapshot
-
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
-
Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss
-
Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates
-
Allogene Therapeutics: Q2 Earnings Snapshot
-
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
-
Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report: Can It Rebound?
-
Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss
-
Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates
-
Allogene Therapeutics: Q1 Earnings Snapshot
-
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
-
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
-
Why Is Allogene Therapeutics (ALLO) Down 19.4% Since Last Earnings Report?
-
Allogene (ALLO) Incurs Narrower-Than-Expected Loss in Q4
-
Allogene Therapeutics (ALLO) Reports Q4 Loss, Misses Revenue Estimates
-
Allogene Therapeutics: Q4 Earnings Snapshot
-
Allogene Therapeutics: Q4 Earnings Snapshot
-
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release